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Abstract: Alterations in epigenomic patterns are associated with diverse physiological functions and pathological mechanisms causing
aging-related diseases, such as degenerative disorders and cancers. We investigated the senescent effects of BIX01294, a G9a (histone
methyltransferase) inhibitor, in human bone marrow mesenchymal stromal cells (hBM-MSCs). We determined the optimal dose and
time of BIX01294 treatment in hBM-MSCs to be 1 µM and 12 h, respectively. Under these conditions, the expression of the antisenescent
genes TERT, bFGF, VEGF, and Oct-4 increased, whereas the expression of the senescent factors p16, p21, and p53 decreased. The
number of β-galactosidase-positive cells decreased significantly, and the rates of migration and cellular protection against oxidative
damage increased in BIX01294-treated MSCs. These data indicate that an optimized dose of BIX01294 may improve the potency and
senescence of stem cells, which may improve the efficacy of stem cell therapy.
Key words: Antiaging, antisenescence, BIX01294, G9a inhibitor, histone methyltransferase, mesenchymal stromal cells

1. Introduction
Stem cells are often expanded under in vitro culture
conditions to obtain sufficient quantities of cells for cell
therapy. However, the cellular protection (Nagai et al.,
2007; Cho et al., 2010b) and differentiation (Pittenger et
al., 1999; Jeong et al., 2013) abilities of stem cells decline
during long-term expansion (Ho et al., 2005; Baumann,
2012). Thus, the risk of cellular senescence increases
in stem cell expansions (Rossi et al., 2007), resulting in
reduced efficacy of cell therapies. This limitation suggests
that stem cells need to be maintained under antisenescent
conditions during long-term expansion.
Epigenetic modifications in DNA and nucleus histones
play a crucial role in regulating chromosomal functions
and gene expression. Recent studies have shown that the
senescent phenotype is induced by increased epigenetic
modifications (Bork et al., 2010), resulting in the
formation of senescence-associated heterochromatin foci
(Kosar et al., 2011; So et al., 2011; Johnson et al., 2012).
The replicative senescence in long-term in vitro cultures
of mesenchymal stromal cells (MSCs) is also caused
by increased DNA methylation in the genome (Choi et
al., 2012). Thus, there is growing evidence that deviant
alterations in the epigenomic patterns are associated
with diverse physiological functions and pathological
* Correspondence: gwcho@chosun.ac.kr

mechanisms causing aging-related diseases, such as
degenerative disorders and cancers (Go et al., 2015; Kang
et al., 2015).
G9a is known as an H3K9 methyltransferase (also
called EHMT2) and it transfers the methyl group to the 9th
lysine residue on histone 3 and plays a role in catalyzing
monomethylation and dimethylation (H3K9me1 and
H3K9me2) in euchromatin (Takahashi et al., 2012; Yuan
et al., 2013). G9a also transfers the methyl group to
nonhistone substrates (Kim et al., 2015). Methylation by
G9a is mostly associated with transcriptional repression,
but in some cases activates gene transcription depending
on the recruited proteins (Tran et al., 2015). G9a is highly
expressed in many cancer tissues compared with normal
tissues (Huang et al., 2010; Cho et al., 2011) and thus it
has been regarded as a therapeutic target for cancer and
cellular senescence.
BIX01294, a selective inhibitor of G9a and the G9a-like
histone methyltransferase (Chang et al., 2009; Yu et al.,
2013), has been developed as an antitumor drug (Kubicek
et al., 2007). It induces transcriptional stimulation by
removing H3K9me2 at the promoters of several tumor
suppressor genes (Nagai et al., 2007). However, BIX01294
enhances the cardiomyogenic potential of bone marrow
mesenchymal stromal cells (BM-MSCs) by inhibiting
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chromatin methylation (Mezentseva et al., 2013). Moreover,
treatment with BIX01294 in embryonic fibroblasts of Oct4/Klf4-transduced mice improves the reprogramming
efficiency of induced pluripotent stem cells (iPSCs) (Shi
et al., 2008), and epigenetic modifications by BIX01294
can increase the ability of adipose-derived mesenchymal
stromal cells to differentiate into endothelial cells (Yang
et al., 2015), suggesting that the effects of epigenetic
regulation by BIX01294 may depend upon the state of the
cells.
We investigated the effects of BIX01294 on cellular
senescence in human BM-MSCs (hBM-MSCs), and
identified that an optimal treatment of BIX01294 leads to
attenuated cellular senescence and improves the stem cell
potency in hBM-MSCs.
2. Materials and methods
2.1. Characteristics of primary human BM-MSCs and
cell culture
The hBM-MSCs were purchased from CEFO (Cell
Engineering For Origin; Seoul, Korea). The cells
were examined for viral infection and mycoplasma
contamination, and all were presented as negative. Flow
cytometric analysis of the cells revealed CD73+, CD105+,
and CD31– phenotypes. The hBM-MSCs were cultured
in T75 flasks (Becton Dickinson; San Jose, CA, USA)
according to the supplier’s recommendations. Cells
were cultivated in hBM-MSC growth medium (DMEM;
Gibco; Grand Island, NY, USA), containing 10% FBS,
l-glutamine, penicillin, and streptomycin, without any
stimulatory supplements or vitamins, and maintained in
a humidified incubator at 37 °C, using a standard mixture
of 95% air and 5% CO2. Cells were subcultured every 5
days, with medium replacement every 3 days. MSCs at
passage 7, 12, or 17 (P-7, P-12, or P-17) were used for these
experiments.

2.2. Real-time PCR
hBM-MSCs were harvested and total RNA was extracted
using RNAiso reagent (TAKARA; Shiga, Japan) according
to the manufacturer’s instructions. The Primescript II
1st strand cDNA synthesis kit (TAKARA; Shiga, Japan)
was used to reverse transcribe 3–5 µg of total RNA with
5 µM Oligo(dT) primers (TAKARA; Shiga, Japan), 1
mM dNTP, and the supplied buffer. First-strand cDNAs
were amplified using the Power SYBR Green PCR master
mix (Applied Biosystems Inc., USA) with gene-specific
primers for human bFGF, Oct-4, p21, p53, TERT, VEGF,
or β-actin. The real-time PCR cycling parameters were as
follows: 95 °C for 10 min, followed by 40 cycles of 15 s at
95 °C, and 1 min at 60 °C. The primers were synthesized by
GenoTech (GenoTech Corp.; Daejeon, South Korea) and
IDT (Integrated DNA Technologies Inc.; Coralville, IA,
USA) and are summarized in the Table.
2.3. MTT assay
The protective effects against H2O2-induced oxidative
stress were measured by MTT assay (Sigma; St. Louis,
MO, USA) according to the manufacturer’s instructions.
Briefly, 2.5 × 103 hBM-MSCs were seeded into each well of
a 96-well plate. The next day, the cells were incubated with
or without 1 µM BIX01294 for 12 h, treated with 0–1.5
mM H2O2 for 1 h, and then subjected to MTT assay.
To examine the cell toxicity effects of BIX01294, MSCs
were incubated with several concentrations (0–5 µM) of
BIX01294 for 12 h and then measured by MTT assay.
2.4. Immunoblot analysis
Cells were extracted by treating them with 40 μL of RIPA
buffer containing protease and dephosphatase inhibitors
(Santa Cruz Biotechnology; Dallas, TX, USA) for 30 min
at 4 °C, and then centrifuged at 16,000 × g for 20 min.
The total proteins were then subjected to immunoblotting
with antibodies specific for TERT (1:500; Santa Cruz
Biotechnology), p53 (1:500; Santa Cruz Biotechnology),
p16 (1:500; Santa Cruz Biotechnology), p21 (1:200;

Table. Oligonucleotides used for real-time RT-PCR.
Gene

Forward primer (5’ ➞ 3’)

Reverse primer (5’ ➞ 3’)

Acc. no.

bFGF

AAAAACGGGGGCTTCTTCCT

ACGGTTAGCACACACTCCTT

NM_002006

TERT

ATCGCCAGCATCATCAAACC

GGTAGAGACGTGGCTCTTGA

NM_198253

Oct4

GCCCGAAAGAGAAAGCGAAC

AACCACACTCGGACCACATC

NM_002701

VEGF

AGAAAATCCCTGTGGGCCTT

GTCACATCTGCAAGTACGTTCG

NM_001025368

p21

GTCTTGTACCCTTGTGCCTC

GGCGTTTGGAGTGGTAGAAA

NM_000389.4

p53

AGGAAATTTGCGTGTGGAGT

AGTGGATGGTTGTACAGTCA

NM_000546

β-actin

ATCCGCAAAGACCTGTACGC

TCTTCATTGTGCTGGGTGCC

NM_001101

Acc. no. indicates gene access number.
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Santa Cruz Biotechnology), angiogenin (ANG, 1:500;
Santa Cruz Biotechnology), cleaved-caspase-3 (1:500;
Santa Cruz Biotechnology), H3k9me2 (1:1000; Merck
Millipore; Darmstadt, Germany), histone 3 (1:2000; Cell
Signaling Technology; Danvers, MA, USA), or β-actin
(1:5000; Sigma; St Louis, MI, USA), and subsequently
to the appropriate horseradish-peroxidase-conjugated
secondary antibodies (1:10,000; Jackson ImmunoResearch
Laboratories; West Grove, PA, USA). The western blots
were quantified with ImageJ (Softonic International, S.A.;
Barcelona, Spain).
2.5. Senescence-associated beta-galactosidase (SA-β-gal)
staining
SA-β-gal staining was carried out using the Senescence
β-Galactosidase Staining kit (Cell Signaling Technology
Inc.) according to the manufacturer’s instructions. The
MSCs were seeded into 6-well plates at a density of 1 × 103
cells/well and incubated until the appropriate confluence
was reached. The cells were washed with PBS and fixed
with 2% formaldehyde and 0.2% glutaraldehyde in
distilled water for 15 min at room temperature. The cells
were then washed twice with PBS containing 1 mM MgCl2
(pH 7.2) and stained overnight in β-galactosidase staining
solution (1 mg/mL X-gal, 5 mM K3Fe[CN]6 (potassium
ferricyanide), 5 mM K4Fe[CN]6 (potassium ferrocyanide),
2 mM MgCl2, 40 mM citric acid/sodium phosphate (pH
6.0), and 150 mM NaCl in distilled water) at 37 °C without
CO2. Images were captured with a microscope (Canon
i-Solution IMTcam3; Tokyo, Japan). The results are
presented as the means of four independent experiments.
2.6. Wound healing test
MSCs were seeded into 6-well plates and incubated
overnight in standard growth medium at 37 °C and 5%
CO2. A uniform scratch was made in the 100% confluent
monolayer culture. The wound was introduced by scraping
the monolayer with a sterile 200-μL pipette tip and then
washing the monolayer with growth medium to remove
cell debris. The cells were then replenished with fresh
growth medium, and wound closure was documented by
photography of the same region at different times (0–18 h).
Migrating cells were counted at each time point (0–18 h).
The results are presented as the means of four independent
experiments.
2.7. Statistical analysis
The data are represented as mean ± standard deviation
(SD) of three or more independent experiments.
Statistical comparisons between groups were made using
an independent t-test. A P-value of < 0.05 was considered
statistically significant.

3. Results
3.1. BIX01294 suppresses the expressions of p53 and p21
in human BM-MSCs
To determine the optimal concentration of BIX01294,
hBM-MSCs were incubated with 0, 0.5, 1, or 1.5 µM
BIX01294 for 12 h. The expressions of senescence-related
genes p53 and p21 were examined by real-time PCR.
Figure 1A shows that the transcripts of the tested genes
were minimal in MSCs treated with 1 µM BIX01294
(Figure 1A; #P < 0.01, mean ± SD, n = 4). To evaluate
the optimal treatment time of BIX01294 in hBM-MSCs,
the cells were incubated with 1 µM BIX01294 for several
incubation times (0–24 h). Decreasing gene expressions
were identified at 12 h of incubation (Figure 1B; *P < 0.05,
#
P < 0.01, mean ± SD, n = 5). Cellular toxicity was not
observed at BIX01294 concentrations of up to 1.5 µM for
12 h, as determined by the MTT assay (Figure 1C; #P <
0.01, mean ± SD, n = 5). From these data, we determined
the optimal treatment conditions in MSCs to be 1 µM
BIX01294 for 12 h.
3.2. The expression of senescence-related factors were
regulated by BIX01294 treatment
We have shown that BIX01294 suppressed the expression
of antisenescent factors at the determined conditions
(Figure 1). To further investigate the role of BIX01294,
various senescent or antisenescent genes were examined
using real-time PCR. Transcripts of the antisenescent
genes TERT, Oct-4, bFGF, and VEGF were significantly
increased in BIX01294-treated MSCs (BIX01294-MSCs)
(Caplan and Dennis, 2006; Meirelles Lda et al., 2009; Oh
et al., 2015), whereas the senescent genes p53 and p21
were decreased compared with nontreated hBM-MSCs
(Control-MSCs) (Figure 2A; t-test, *P < 0.05, #P < 0.01,
mean ± SD, n = 4). Consistent results were obtained from
immunoblot analysis with specific antibodies against
TERT, p53, p16, p21, and H3K9me2 (Figure 2B).
3.3. BIX01294 prevented cellular senescence in hBMMSCs
We have shown that senescence-related factors were
modulated following BIX01294 treatment. To examine this
effect in replicative senescent MSCs, MSCs were cultured
up to passage 17 (P-17) according to the procedures
described in the Materials and methods. Cells at P-7, P-12,
and P-17 were incubated with or without BIX01294 (1 µM
BIX01294 for 12 h) and subjected to SA-β-gal assays (Figure
3A). The number of SA-β-gal-stained cells increased with
increasing passage number. Meanwhile, the number of
SA-β-gal-stained cells decreased at BIX01294-treated
MSCs in comparison with nontreated MSCs (Figure 3B;
t-test, #P < 0.01, mean ± SD, n = 4). Immunoblot analyses
with senescent proteins showed decreasing expressions
of p53 and p16, and an increasing expression of TERT in
BIX01294-treated MSCs (P-12; Figure 3C).
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Figure 1. BIX01294 reduces the expression of the p53 and p21 genes in hBM-MSCs. (A) The expressions of p53 and p21 in MSCs
treated with BIX01294 (0–1.5 µM) for 12 h were measured by real-time PCR. (B) The suppressed expressions were maximal at 12 h of
incubation with 1 µM BIX01294 treatment, as measured by real-time PCR. (C) No cytotoxicity was observed in MSCs treated with up
to 1.5 µM BIX01294, as tested by MTT assay.

Figure 2. Transcripts of the senescence-related factors were regulated by BIX01294-treated hBM-MSCs. (A) The expressions of the
antisenescent factors TERT, bFGF, VEGF, and Oct-4 increased significantly, whereas those of the senescent factors p21 and p53 decreased
significantly in BIX01294-MSCs. (B) The expressions were confirmed by immunoblot analysis with antibodies specific for TERT, p53,
p16, p21, or H3K9me2.
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Figure 3. BIX01294 prevents cellular senescence in hBM-MSCs. (A) Senescence-associated beta-galactosidase (SA-β-gal) assays were
performed in BIX01294-treated (BIX01294-MSCs; 1 µM, 12 h) or nontreated MSCs (Control-MSCs) at P-7, P-12, and P-17. P-7, P-12,
and P-17 indicate passages 7, 12, and 17. The senescent cells are indicated by the blue staining. (B) The number of total cells and senescent
cells (blue) were counted and the results are presented graphically. (C) Immunoblot analysis was performed with the senescence-related
proteins p16, p53, and TERT in BIX01294-treated or nontreated P-12 MSCs.

3.4. BIX01294 improved cellular migration in hBMMSCs
The migratory ability of stem cells is associated with
stem cell potency (Maxson et al., 2012). To examine the
migratory effects of BIX01294, MSCs were incubated
with or without 1 µM BIX01294 for 12 h. Cells were then
tested with a wound healing assay (Figure 4A). Increased
migration rates were observed in BIX01294-treated MSCs
(Figure 4B; t-test, #P < 0.01, mean ± SD, n = 3). To confirm

these results at the protein level (Cho et al., 2010a),
immunoblot analysis was performed with antibodies
against ANG and β-actin, and increasing expressions were
identified in BIX01294-MSCs (Figure 4C).
3.5. Protective effects of BIX01294 in hBM-MSCs
Since BIX01294 increased the expression of antisenescent
factors in MSCs, we examined the cell-protective effects
in BIX01294-treated MSCs. BIX01294-MSCs were
exposed to H2O2 (0–1.5 mM) for 1 h and then subjected
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Figure 4. BIX01294 improves the cellular migration of hBM-MSCs. (A) The migration of BIX01294-treated MSCs was observed for
18 h after being scratched (inside dotted line). (B) Migrated MSCs inside the dotted lines were counted. (C) Immunoblot analysis was
performed with the migration marker protein, ANG.

to a cell viability assay. The viability of BIX01294-MSCs
was significantly greater than that of nontreated MSCs
(Control-MSCs) (Figure 5A; t-test, *P < 0.05, #P < 0.01,
mean ± SD, n = 5). To confirm the protective effects at the
protein level, immunoblot analysis was performed with
antibodies against cleaved caspase-3 and β-actin, and
consistent results were obtained (Figure 5B).
4. Discussion
G9a has been studied as a therapeutic target for cancers
(Huang et al., 2010; Cho et al., 2011). However, the
G9a inhibitor BIX01294 improves stem cell potency
(Mezentseva et al., 2013; Yang et al., 2015) and
reprogramming efficiency (Shi et al., 2008), suggesting
that the effects of BIX01294 may vary depending on cell
type, treatment dose, and exposure time. In this study, we
assessed the effects of BIX01294 under various doses and
times using human BM-MSCs (Figure 1). We identified
that a 12-h treatment at a low micromolar concentration of
BIX01294 (1 µM) decreased the expression of the senescent
genes p53 and p21, whereas high doses of BIX01294 and
longer treatment times did not (Figure 1). With further
investigation under the determined conditions (1 µM
BIX01294 for 12 h), we observed increasing expressions of
the antisenescent factors bFGF, TERT, Oct-4, and VEGF,
and decreasing expressions of the senescent factors p21,
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p16, and p53 in BIX01294-treated MSCs (Figure 2). These
data suggest the possibility of antisenescent effects in
BIX01294-treated hBM-MSCs.
It is well known that increasing replicative senescence
caused by continuing subcultivation can induce the
expression of the senescence-associated serial proteins
p53, p16, and p21 (Kim et al., 2015). Since we have shown
that low doses of BIX01294 modulated the expression
of senescence-associated factors in MSCs (Figure 2),
BIX01294-MSCs may attenuate cellular senescence
in hBM-MSCs. To examine this, SA-β-gal assays were
performed on BIX01294-treated MSCs. The number of
senescent cells was lower in BIX01294-treated MSCs than
in the nontreated MSCs (Control-MSCs; Figures 3A and
3B). Similar results were obtained in long-term cultures of
MSCs (P-12, P-17; Figures 3C and 3D).
Migration and protective ability are also important
factors for stem cell potency. In cell therapy, injected stem
cells migrate toward the site of injured cells (Jeong et al.,
2015) and protect themselves from inflammatory attacks
(Hong et al., 2015). We showed that BIX01294 induced
the expression of antisenescent proteins and decreased
prosenescent proteins, suggesting that BIX01294 treatment
may improve the migration and protection of MSCs. As
shown in Figures 4 and 5, BIX01294 treatment increased
the migration ability (Figure 4) and protective effects

AHN et al. / Turk J Biol

Figure 5. Protective effects of BIX01294 in hBM-MSCs. (A) BIX01294-pretreated MSCs were exposed to 0–1.5 mM H2O2 and the cell
viabilities were examined by MTT assay. (B) Immunoblot analysis was performed with antibodies specific for cleaved caspase-3 or β-actin.

against damage induced by oxidative stress in the BMMSCs (Figures 5). Thus, BIX01294 induces antisenescent
effects by transcriptional modulations of senescenceassociated genes.
We have described the antisenescent effects in
BIX01294-treated MSCs. However, there are limitations to
this study; we were unable to confirm whether or not this
modulation is direct. Based on the functional mechanism
of BIX01294 as a histone methyltransferase inhibitor, it
is possible that BIX01294 induction acts to decrease the
number of dimethylated histones on their chromatin,
thereby activating many gene loci and regulating the
expression of various genes. Therefore, global genomic
analysis of BIX01294-MSCs may provide a better picture
of how the global genes are modulated by BIX01294, which
may offer clues to understanding the overall mechanisms
of BIX01294.
In conclusion, we have investigated the antisenescent
effects of BIX01294 in hBM-MSCs and confirmed its
attenuation of cellular senescence. The antisenescent effects
of BIX01294 were achieved through the expression of
senescence-related genes. An optimized dose of BIX01294
may improve stem cell potency and cellular senescence,
which may provide better efficacy in stem cell therapy.
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